Unveiling the Immunomodulatory and regenerative potential of iPSC-derived mesenchymal stromal cells and their extracellular vesicles.
Macrophage polarization
T cell proliferation
Wound healing
iMSC-derived extracellular vesicles
iPSC-derived MSCs
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 10 2024
15 10 2024
Historique:
received:
27
06
2024
accepted:
09
10
2024
medline:
16
10
2024
pubmed:
16
10
2024
entrez:
15
10
2024
Statut:
epublish
Résumé
Induced pluripotent stem cell (iPSC)-derived mesenchymal stromal cells (iMSCs) offer a promising alternative to primary mesenchymal stromal cells (MSCs) and their derivatives, particularly extracellular vesicles (EVs), for use in advanced therapy medicinal products. In this study we evaluated the immunomodulatory and regenerative potential of iMSCs as well as iMSC-EVs, alongside primary human umbilical cord-derived mesenchymal stromal cells (hUCMSCs). Our findings demonstrate that iMSCs exhibit comparable abilities to hUCMSCs in regulating lymphocyte proliferation and inducing an anti-inflammatory phenotype in monocytes. We also observed decreased TNFα levels and increased IL-10 induction, indicating a potential mechanism for their immunomodulatory effects. Furthermore, iMSC-EVs also showed effective immunomodulation by inhibiting T cell proliferation and inducing macrophage polarization similar to their parental cells. Additionally, iMSC-EVs exhibited pro-regenerative potential akin to hUCMSC-EVs in in vitro scratch assays. Notably, priming iMSCs with pro-inflammatory cytokines significantly enhanced the immunomodulatory potential of iMSC-EVs. These results underscore the considerable promise of iMSCs and iMSCs-EVs as an alternate source for MSC-derived therapeutics, given their potent immunomodulatory and regenerative properties.
Identifiants
pubmed: 39407038
doi: 10.1038/s41598-024-75956-3
pii: 10.1038/s41598-024-75956-3
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24098Informations de copyright
© 2024. The Author(s).
Références
Squillaro, T., Peluso, G. & Galderisi, U. Clinical trials with mesenchymal stem cells: an update. Cell. Transpl. 25 (5), 829–848 (2016).
doi: 10.3727/096368915X689622
Hynes, K., Menicanin, D., Mrozik, K., Gronthos, S. & Bartold, P. M. Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines. Stem Cells Dev. 23 (10), 1084–1096 (2014).
pubmed: 24367908
doi: 10.1089/scd.2013.0111
Lian, Q. et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 121 (9), 1113–1123 (2010).
pubmed: 20176987
doi: 10.1161/CIRCULATIONAHA.109.898312
Robinton, D. A. & Daley, G. Q. The promise of induced pluripotent stem cells in research and therapy. Nature. 481 (7381), 295–305 (2012).
pubmed: 22258608
pmcid: 3652331
doi: 10.1038/nature10761
Ng, J. et al. Immunomodulatory properties of Induced Pluripotent Stem cell-derived mesenchymal cells. J. Cell. Biochem. 117 (12), 2844–2853 (2016).
pubmed: 27167148
doi: 10.1002/jcb.25596
Dupuis, V. & Oltra, E. Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: mesenchymal stem cells from induced pluripotent stem cells. World J. Stem Cells. 13 (8), 1094–1111 (2021).
pubmed: 34567428
pmcid: 8422924
doi: 10.4252/wjsc.v13.i8.1094
Zhou, A. K. et al. Using Pre-clinical studies to explore the potential clinical uses of Exosomes secreted from Induced Pluripotent Stem cell-derived mesenchymal stem cells. Tissue Eng. Regen Med. 20 (6), 793–809 (2023).
pubmed: 37651091
pmcid: 10519927
doi: 10.1007/s13770-023-00557-6
Bloor, A. J. C. et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat. Med. 26 (11), 1720–1725 (2020).
pubmed: 32929265
doi: 10.1038/s41591-020-1050-x
Saetersmoen, M. L., Hammer, Q., Valamehr, B., Kaufman, D. S. & Malmberg, K. J. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Semin Immunopathol. 41 (1), 59–68 (2019).
pubmed: 30361801
doi: 10.1007/s00281-018-0721-x
McGrath, M. et al. GMP-compatible and xeno-free cultivation of mesenchymal progenitors derived from human-induced pluripotent stem cells. Stem Cell. Res. Ther. 10 (1), 11 (2019).
pubmed: 30635059
pmcid: 6329105
doi: 10.1186/s13287-018-1119-3
Fernandez-Rebollo, E. et al. Senescence-Associated Metabolomic phenotype in primary and iPSC-Derived mesenchymal stromal cells. Stem Cell. Rep. 14 (2), 201–209 (2020).
doi: 10.1016/j.stemcr.2019.12.012
Luo, L. et al. Feeder-free generation and transcriptome characterization of functional mesenchymal stromal cells from human pluripotent stem cells. Stem Cell. Res. 48, 101990 (2020).
pubmed: 32950887
doi: 10.1016/j.scr.2020.101990
Ozay, E. I. et al. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of graft-vs-host disease. Stem Cell. Res. 35, 101401 (2019).
pubmed: 30738321
pmcid: 6544140
doi: 10.1016/j.scr.2019.101401
Chang, Y. H., Wu, K. C. & Ding, D. C. Induced Pluripotent Stem Cell-differentiated chondrocytes repair cartilage defect in a rabbit osteoarthritis model. Stem Cells Int. 2020, 8867349 (2020).
pubmed: 33224204
pmcid: 7671807
doi: 10.1155/2020/8867349
Sabapathy, V. & Kumar, S. hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine. J. Cell. Mol. Med. 20 (8), 1571–1588 (2016).
pubmed: 27097531
pmcid: 4956943
doi: 10.1111/jcmm.12839
Gao, W-X. et al. Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells.
Colter, D. C., Class, R., DiGirolamo, C. M. & Prockop, D. J. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc. Natl. Acad. Sci. U S A. 97 (7), 3213–3218 (2000).
pubmed: 10725391
pmcid: 16218
doi: 10.1073/pnas.97.7.3213
Zuk, P. A. et al. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell. 13 (12), 4279–4295 (2002).
pubmed: 12475952
pmcid: 138633
doi: 10.1091/mbc.e02-02-0105
Miranda, R. A., Galván Cabrera, J. A. & de León Delgado, J. Propiedades inmunomoduladoras de las células madre mesenquimales. Revista Cubana de Hematología, Inmunología y Hemoterapia. ;31:20–31. (2015).
Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell. Biol. 200 (4), 373–383 (2013).
pubmed: 23420871
pmcid: 3575529
doi: 10.1083/jcb.201211138
Nawaz, M. et al. Extracellular vesicles: evolving factors in Stem Cell Biology. Stem Cells Int. 2016, 1073140 (2016).
pubmed: 26649044
doi: 10.1155/2016/1073140
Wen, S. et al. Mesenchymal stromal cell-derived extracellular vesicles rescue radiation damage to murine marrow hematopoietic cells. Leukemia. 30 (11), 2221–2231 (2016).
pubmed: 27150009
pmcid: 5093052
doi: 10.1038/leu.2016.107
de Godoy, M. A. et al. Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-beta oligomers. J. Biol. Chem. 293 (6), 1957–1975 (2018).
pubmed: 29284679
doi: 10.1074/jbc.M117.807180
Phinney, D. G. & Pittenger, M. F. Concise Review: MSC-Derived exosomes for cell-free therapy. Stem Cells. 35 (4), 851–858 (2017).
pubmed: 28294454
doi: 10.1002/stem.2575
Chang, M. G. et al. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation. 113 (15), 1832–1841 (2006).
pubmed: 16606790
doi: 10.1161/CIRCULATIONAHA.105.593038
Breitbach, M. et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 110 (4), 1362–1369 (2007).
pubmed: 17483296
doi: 10.1182/blood-2006-12-063412
Giuliani, M. et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood. 118 (12), 3254–3262 (2011).
pubmed: 21803852
doi: 10.1182/blood-2010-12-325324
Zhu, Y. et al. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell. Res. Ther. 8 (1), 64 (2017).
pubmed: 28279188
pmcid: 5345222
doi: 10.1186/s13287-017-0510-9
Lai, R. C. et al. Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell. Res. 4 (3), 214–222 (2010).
pubmed: 20138817
doi: 10.1016/j.scr.2009.12.003
Zhang, J. et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J. Transl Med. 13, 49 (2015).
pubmed: 25638205
pmcid: 4371881
doi: 10.1186/s12967-015-0417-0
Peng, W. et al. Small extracellular vesicles secreted by iPSC-Derived MSCs ameliorate pulmonary inflammation and lung Injury Induced by Sepsis through Delivery of miR-125b-5p. J. Immunol. Res. 2023, 8987049 (2023).
pubmed: 37425491
pmcid: 10329558
doi: 10.1155/2023/8987049
Ye, T. et al. Large extracellular vesicles secreted by human iPSC-derived MSCs ameliorate tendinopathy via regulating macrophage heterogeneity. Bioact Mater. 21, 194–208 (2023).
pubmed: 36101856
Kim, H. et al. Identification of molecules responsible for Therapeutic effects of Extracellular vesicles produced from iPSC-Derived MSCs on Sjo¨gren’s syndrome. Aging Dis. 12 (6), 1409–1422 (2021).
pubmed: 34527418
pmcid: 8407887
doi: 10.14336/AD.2021.0621
Hai, B., Shigemoto-Kuroda, T., Zhao, Q., Lee, R. H. & Liu, F. Inhibitory effects of iPSC-MSCs and their extracellular vesicles on the onset of Sialadenitis in a mouse model of Sjögren’s syndrome. Stem Cells Int. 2018, 2092315 (2018).
pubmed: 29736173
pmcid: 5875028
doi: 10.1155/2018/2092315
Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8 (4), 315–317 (2006).
pubmed: 16923606
doi: 10.1080/14653240600855905
Cruz-Barrera, M. et al. Integrated Analysis of Transcriptome and Secretome from umbilical cord mesenchymal stromal cells reveal New mechanisms for the modulation of inflammation and Immune Activation. Front. Immunol. 11, 575488 (2020).
pubmed: 33117373
pmcid: 7561386
doi: 10.3389/fimmu.2020.575488
Németh, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15 (1), 42–49 (2009).
pubmed: 19098906
doi: 10.1038/nm.1905
Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell. Biol. ; (2006). Chap. 3:Unit 3.22.
Zhang, J. et al. Induced Pluripotent Stem cell-derived mesenchymal stem cells hold Lower Heterogeneity and Great Promise in Biological Research and clinical applications. Front. Cell. Dev. Biol. 9, 716907 (2021).
pubmed: 34660579
pmcid: 8514743
doi: 10.3389/fcell.2021.716907
Nagamura-Inoue, T. & He, H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J. Stem Cells. 6 (2), 195–202 (2014).
pubmed: 24772246
pmcid: 3999777
doi: 10.4252/wjsc.v6.i2.195
Ma, D. et al. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int. Immunopharmacol. 74, 105687 (2019).
pubmed: 31295689
doi: 10.1016/j.intimp.2019.105687
Kimbrel, E. A. et al. Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev. 23 (14), 1611–1624 (2014).
pubmed: 24650034
pmcid: 4086362
doi: 10.1089/scd.2013.0554
Polo, J. M. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28 (8), 848–855 (2010).
pubmed: 20644536
pmcid: 3148605
doi: 10.1038/nbt.1667
Di Nicola, M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99 (10), 3838–3843 (2002).
pubmed: 11986244
doi: 10.1182/blood.V99.10.3838
Meisel, R. et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 103 (12), 4619–4621 (2004).
pubmed: 15001472
doi: 10.1182/blood-2003-11-3909
Beyth, S. et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood. 105 (5), 2214–2219 (2005).
pubmed: 15514012
doi: 10.1182/blood-2004-07-2921
Wada, N., Gronthos, S. & Bartold, P. M. Immunomodulatory effects of stem cells. Periodontol 2000. 63 (1), 198–216 (2013).
pubmed: 23931061
doi: 10.1111/prd.12024
Sivanathan, K. N., Gronthos, S., Rojas-Canales, D., Thierry, B. & Coates, P. T. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell. Rev. Rep. 10 (3), 351–375 (2014).
pubmed: 24510581
doi: 10.1007/s12015-014-9495-2
Fu, X. et al. Comparison of immunological characteristics of mesenchymal stem cells derived from human embryonic stem cells and bone marrow. Tissue Eng. Part. A. 21 (3–4), 616–626 (2015).
pubmed: 25256849
pmcid: 4334098
doi: 10.1089/ten.tea.2013.0651
Schnabel, L. V. et al. Induced pluripotent stem cells have similar immunogenic and more potent immunomodulatory properties compared with bone marrow-derived stromal cells in vitro. Regen Med. 9 (5), 621–635 (2014).
pubmed: 24773530
doi: 10.2217/rme.14.29
Ranganath, S. H., Levy, O., Inamdar, M. S. & Karp, J. M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell. Stem Cell. 10 (3), 244–258 (2012).
pubmed: 22385653
pmcid: 3294273
doi: 10.1016/j.stem.2012.02.005
Ankrum, J. A., Ong, J. F. & Karp, J. M. Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32 (3), 252–260 (2014).
pubmed: 24561556
pmcid: 4320647
doi: 10.1038/nbt.2816
Yu, Y. et al.
Kourembanas, S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu. Rev. Physiol. 77, 13–27 (2015).
pubmed: 25293529
doi: 10.1146/annurev-physiol-021014-071641
Zhang, B. et al. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev. 23 (11), 1233–1244 (2014).
pubmed: 24367916
doi: 10.1089/scd.2013.0479
Mitsialis, S. A. & Kourembanas, S. Stem cell-based therapies for the newborn lung and brain: possibilities and challenges. Semin Perinatol. 40 (3), 138–151 (2016).
pubmed: 26778234
pmcid: 4808378
doi: 10.1053/j.semperi.2015.12.002
Wang, Y., Chen, X., Cao, W. & Shi, Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 15 (11), 1009–1016 (2014).
pubmed: 25329189
doi: 10.1038/ni.3002
Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell. Stem Cell. 2 (2), 141–150 (2008).
pubmed: 18371435
doi: 10.1016/j.stem.2007.11.014
Song, Y. et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of Interleukin-1β-Primed mesenchymal stem cells against Sepsis. Stem Cells. 35 (5), 1208–1221 (2017).
pubmed: 28090688
doi: 10.1002/stem.2564
Ti, D. et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. J. Translational Med. ;13(1). (2015).
Kobayashi, H. et al. <Editors’ Choice> effects of exosomes derived from the induced pluripotent stem cells on skin wound healing. Nagoya J. Med. Sci. 80 (2), 141–153 (2018).
pubmed: 29915432
pmcid: 5995743
Kim, S., Lee, S. K., Kim, H. & Kim, T. M. Exosomes secreted from Induced Pluripotent Stem cell-derived mesenchymal stem cells accelerate skin cell proliferation. Int. J. Mol. Sci. ;19(10). (2018).
Santoso, M. R. et al. Exosomes from Induced Pluripotent Stem Cell-Derived cardiomyocytes promote autophagy for myocardial repair. J. Am. Heart Assoc. 9 (6), e014345 (2020).
pubmed: 32131688
pmcid: 7335524
doi: 10.1161/JAHA.119.014345
Gao, L. et al. Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. Sci. Transl Med. ;12(561). (2020).
Wang, Y. et al. Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int. J. Cardiol. 192, 61–69 (2015).
pubmed: 26000464
pmcid: 4469495
doi: 10.1016/j.ijcard.2015.05.020
Qi, X. et al. Exosomes secreted by Human-Induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and Osteogenesis in osteoporotic rats. Int. J. Biol. Sci. 12 (7), 836–849 (2016).
pubmed: 27313497
pmcid: 4910602
doi: 10.7150/ijbs.14809
Liu, X. et al. Exosomes secreted from Human-Induced pluripotent stem cell-derived mesenchymal stem cells prevent osteonecrosis of the femoral head by promoting angiogenesis. Int. J. Biol. Sci. 13 (2), 232–244 (2017).
pubmed: 28255275
pmcid: 5332877
doi: 10.7150/ijbs.16951
Rani, S., Ryan, A. E., Griffin, M. D. & Ritter, T. Mesenchymal stem cell-derived Extracellular vesicles: toward cell-free therapeutic applications. Mol. Ther. 23 (5), 812–823 (2015).
pubmed: 25868399
pmcid: 4427881
doi: 10.1038/mt.2015.44
El-Tookhy, O. S., Shamaa, A. A., Shehab, G. G., Abdallah, A. N. & Azzam, O. M. Histological evaluation of experimentally Induced critical size defect skin wounds using Exosomal Solution of mesenchymal stem cells derived microvesicles. Int. J. Stem Cells. 10 (2), 144–153 (2017).
pubmed: 29084422
pmcid: 5741195
doi: 10.15283/ijsc17043
Sharma, G. D., He, J. & Bazan, H. E. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J. Biol. Chem. 278 (24), 21989–21997 (2003).
pubmed: 12663671
doi: 10.1074/jbc.M302650200
Shabbir, A., Cox, A., Rodriguez-Menocal, L., Salgado, M. & Van Badiavas, E. Mesenchymal stem cell exosomes induce Proliferation and Migration of normal and chronic wound fibroblasts, and enhance Angiogenesis in Vitro. Stem Cells Dev. 24 (14), 1635–1647 (2015).
pubmed: 25867197
pmcid: 4499790
doi: 10.1089/scd.2014.0316
Tertel, T., Dittrich, R., Arsène, P., Jensen, A. & Giebel, B. EV products obtained from iPSC-derived MSCs show batch-to-batch variations in their ability to modulate allogeneic immune responses in vitro. Front. Cell. Dev. Biol. 11, 1282860 (2023).
pubmed: 37965578
pmcid: 10642442
doi: 10.3389/fcell.2023.1282860